

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GREEN INTERNATIONAL

Holdings Limited

格林國際控股有限公司

GREEN INTERNATIONAL HOLDINGS LIMITED

格林國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2700)

**ANNUAL RESULTS ANNOUNCEMENT
FOR THE YEAR ENDED 31 DECEMBER 2022**

The board (the “**Board**”) of directors (the “**Directors**”) of Green International Holdings Limited (the “**Company**”) announces the audited consolidated annual results of the Company and its subsidiaries (collectively referred to as the “**Group**”) for the year ended 31 December 2022, together with the comparative figures for the corresponding year in 2021, as follows:

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the year ended 31 December 2022

	Notes	2022 HK\$'000	2021 HK\$'000
Continuing operations:			
Revenue	4	47,236	69,057
Direct costs and operating expenses		<u>(21,089)</u>	<u>(31,451)</u>
Gross profit		26,147	37,606
Other incomes, gains and losses, net	5	2,779	(563)
Selling expenses		(12,647)	(21,347)
Administrative expenses		(23,821)	(37,441)
Impairment loss of goodwill		–	(8,566)
Impairment loss of trademark user right and technical know-how		(1,295)	(11,027)
Impairment loss of property, plant and equipment		(651)	(8,569)
Impairment loss of right-of-use assets		(1,039)	(18,971)
Finance costs	6	<u>(3,330)</u>	<u>(4,189)</u>
Loss before income tax	7	(13,857)	(73,067)
Income tax credit/(expenses)	8	43	(342)
Loss for the year from continuing operations		<u>(13,814)</u>	<u>(73,409)</u>
Discontinued operations:			
Profit for the year from discontinued operations	9	–	1,149
Loss for the year		<u>(13,814)</u>	<u>(72,260)</u>
Attributable to owners of the Company			
— Loss from continuing operations		(13,229)	(70,329)
— Profit from discontinued operations		–	1,149
		<u>(13,229)</u>	<u>(69,180)</u>
Loss for the year attributable to non-controlling interest			
— from continuing operations		(585)	(3,080)
— from discontinued operations		–	–
		<u>(585)</u>	<u>(3,080)</u>
Loss for the year		<u>(13,814)</u>	<u>(72,260)</u>
Loss per share for loss for the year attributable to the equity holders of the Company			
— from continuing operations			
Basic and diluted (<i>HK cents per share</i>)	10	(2.00)	(10.66)
— from continuing and discontinued operations			
Basic and diluted (<i>HK cents per share</i>)	10	<u>(2.00)</u>	<u>(10.48)</u>

**CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME**

For the year ended 31 December 2022

	2022	2021
	<i>HK\$'000</i>	<i>HK\$'000</i>
Loss for the year	(13,814)	(72,260)
Other comprehensive (expense)/income, net of tax		
— Exchange differences arising during the year	<u>(966)</u>	<u>280</u>
Total comprehensive expenses for the year	<u>(14,780)</u>	<u>(71,980)</u>
Total comprehensive expenses for the year attributable to:		
— Equity holders of the Company	(14,064)	(68,939)
— Non-controlling interests	<u>(716)</u>	<u>(3,041)</u>
	<u>(14,780)</u>	<u>(71,980)</u>
Total comprehensive (expenses)/income for the year attributable to:		
— from continuing operations	(14,780)	(73,129)
— from discontinued operations	<u>—</u>	<u>1,149</u>
	<u>(14,780)</u>	<u>(71,980)</u>

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2022

	<i>Notes</i>	2022 <i>HK\$'000</i>	2021 <i>HK\$'000</i>
ASSETS			
Non-current assets			
Property, plant and equipment		9,459	13,461
Right-of-use assets		45,302	51,947
Trademark user right and technical know-how		10,219	11,514
Prepayments		3,912	–
		<u>68,892</u>	<u>76,922</u>
Current assets			
Inventories		7,689	9,319
Trade receivables	12	2,855	11,137
Prepayments, deposits and other receivables		7,459	6,692
Bank balances and cash		81,742	110,743
		<u>99,745</u>	<u>137,891</u>
Total assets		<u>168,637</u>	<u>214,813</u>
EQUITY			
Capital and reserves attributable to the equity holders of the Company			
Share capital	15	131,979	131,979
Reserves		(79,792)	(65,728)
		<u>52,187</u>	<u>66,251</u>
Non-controlling interests		<u>2,348</u>	<u>3,064</u>
Total equity		<u>54,535</u>	<u>69,315</u>

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2022

	<i>Notes</i>	2022 <i>HK\$'000</i>	2021 <i>HK\$'000</i>
LIABILITIES			
Non-current liabilities			
Bonds payables		5,366	4,897
Lease liabilities		49,754	62,912
Deferred tax liabilities		1,021	1,151
		<u>56,141</u>	<u>68,960</u>
Current liabilities			
Trade payables	<i>13</i>	4,599	4,255
Contract liabilities		189	3,599
Accruals and other payables	<i>14</i>	40,589	56,113
Lease liabilities		12,581	12,552
Tax payable		3	19
		<u>57,961</u>	<u>76,538</u>
Total liabilities		114,102	145,498
Total equity and liabilities		168,637	214,813
Net current assets		41,784	61,353
Total assets less current liabilities		110,676	138,275

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1. GENERAL INFORMATION

The Company was incorporated in the Cayman Islands on 8 March 2006 as an exempted company with limited liability. Its registered office is situated at Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands. The shares of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in 2006. Its parent company is Jumbo Faith International Limited (“**Jumbo Faith**”), which is wholly owned by Ms. Zhou Cuiqiong, mother of Mr. Yu Zhoujie (a non-executive Director and the Chairman of the Company).

The Group was principally engaged in provision of (i) health and medical services and (ii) beauty and wellness products and related services.

These consolidated financial statements are presented in Hong Kong dollars (“**HK\$**”), which is also the Company’s functional currency, and all values are rounded to the nearest thousand (“**HK\$’000**”), except when otherwise indicated.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

2.1 Statement of compliance

These consolidated financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards (“**HKFRSs**”) (which include all Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards (“**HKASs**”) and Interpretations) issued by the Hong Kong Institute of Certified Public Accountants (“**HKICPA**”) and accounting principles generally accepted in Hong Kong. In addition, the consolidated financial statements include applicable disclosures required by the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) and the applicable disclosure requirements of the Hong Kong Companies Ordinance (Cap. 622) relating to the preparation of consolidated financial statements.

The preparation of consolidated financial statements in conformity with HKFRSs requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

2.2 Application of New and Amendments to Hong Kong Financial Reporting Standards

Amendments to HKFRSs that are mandatorily effective for the current year

In the current year, the Group has applied the following amendments to HKFRSs issued by the Hong Kong Institute of Certified Public Accountant (“HKICPA”) for the first time, which are mandatorily effective for their annual reporting period commencing 1 January 2022 for the preparation of consolidated financial statements:

Amendments to HKFRS 3	Reference to the Conceptual Framework
Amendment to HKFRS 16	Covid-19-Related Rent Concessions beyond 30 June 2021
Amendments to HKAS 16	Property, Plant and Equipment — Proceeds before Intended Use
Amendments to HKAS 37	Onerous Contracts — Cost of Fulfilling a Contract
Amendments to HKFRSs	Annual Improvements to HKFRSs 2018-2020

The application of the amendments to HKFRSs in the current year has had no material impact on the Group’s financial positions and performance for the current and prior years and/or on the disclosures set out in these consolidated financial statements.

2.3 New and Amendments to HKFRS in issued but not yet effective

HKFRS 17 (including the October 2020 and February 2022 Amendments to HKFRS 17)	Insurance Contracts ¹
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture ²
Amendments to HKFRS 16	Lease Liability in a Sale and Leaseback ³
Amendments to HKAS 1	Classification of Liabilities as Current or Non-current and related amendments to Hong Kong Interpretation 5 (2020) ³
Amendments to HKAS 1	Non-current Liabilities with Covenants ³
Amendments to HKAS 1 and HKFRS Practice Statement 2	Disclosure of Accounting Policies ¹
Amendments to HKAS 8	Definition of Accounting Estimates ¹
Amendments to HKAS 12	Deferred Tax related to Assets and Liabilities arising from a Single Transaction ¹

¹ Effective for annual periods beginning on or after 1 January 2023.

² Effective for annual periods beginning on or after a date to be determined.

³ Effective for annual periods beginning on or after 1 January 2024.

The directors anticipate that the application of all new and amendments to HKFRSs will have no material impact on the consolidated financial statements in the foreseeable future.

3. REVENUE AND SEGMENT INFORMATION

The Group primarily operates in Hong Kong and the People's Republic of China (the "PRC"). The Group's operating businesses are structured and managed separately according to the nature of their operations and the products or services they provide. Each of the Group's business units represents a strategic business unit that offers products or services which are subject to risks and returns that are different from those of the other business units. The Group's business units are as follows:

- (a) the health and medical segment, which is engaged in the operation of health and medical related businesses of its clubhouse (which was closed in 2021), hemodialysis center and hospital; and
- (b) the beauty and wellness segment, which is engaged in selling of beauty and wellness products and related services.

The information reported below does not include any amounts for the discontinued operations, which are disclosed separately in more details in Note (9).

The discontinued operations represents the operations of the financial segment which was previously engaged in securities brokerage, advising on securities and asset management businesses but were discontinued by the Group upon the disposal of Green Securities Limited and Green Asset Management in March 2021.

Operating segments are identified for financial reporting purposes in a manner consistent with the internal reporting provided to the chief operating decision-maker. The Board has been identified as the Group's chief operating decision-maker.

Inter-segment revenue is eliminated on consolidation. Inter-segment sales and transfers are transacted according to the relevant prevailing market prices.

Segment results are presented as operating profit or loss.

3.1 Revenue of the Group, together with the analysis of the revenue by segments and geographical regions are as follows:

	Health and medical business HK\$'000	Beauty and wellness business HK\$'000	Total HK\$'000
For the year ended 31 December 2022			
The PRC			
— At a point in time	<u>31,806</u>	<u>15,430</u>	<u>47,236</u>

Health and medical business <i>HK\$'000</i>	Beauty and wellness business <i>HK\$'000</i>	Total <i>HK\$'000</i>
--	---	--------------------------

For the year ended 31 December 2021

The PRC

— At a point in time	<u>39,930</u>	<u>29,127</u>	<u>69,057</u>
----------------------	---------------	---------------	---------------

The geographic location analysis of revenue is allocated based on the geographic location of customers and the operating geographic location of the health and medical business and beauty and wellness business. For the years ended 31 December 2022 and 2021, no single customer's revenue accounted for more than 10% of the Group's total revenue.

3.2 Results by operating segments are as follows:

	2022 <i>HK\$'000</i>	2021 <i>HK\$'000</i>
Continuing operations:		
Health and medical business (<i>Note (i)</i>)	658	(19,557)
Beauty and wellness business (<i>Note (ii)</i>)	<u>(2,399)</u>	<u>(33,250)</u>
Total net operating loss by operating segments	(1,741)	(52,807)
Unallocated corporate expenses, net	(7,610)	(15,686)
Net allowance of expected credit loss on other receivables	(1,176)	(385)
Finance costs	<u>(3,330)</u>	<u>(4,189)</u>
Loss before income tax	(13,857)	(73,067)
Income tax credit/(expenses)	<u>43</u>	<u>(342)</u>
Loss for the year from continuing operations	<u>(13,814)</u>	<u>(73,409)</u>

Notes:

- (i) For the year ended 31 December 2022, impairment loss of goodwill, property, plant and equipment and right-of-use assets of approximately HK\$Nil (2021: HK\$8,566,000), HK\$Nil (2021:HK\$1,089,000) and HK\$Nil (2021:HK\$6,348,000) respectively and loss on disposal of property, plant and equipment of approximately HK\$19,000 (2021:HK\$143,000) were included within the health and medical business segment.
- (ii) For the year ended 31 December 2022, impairment loss of trademark user right and technical know-how, property, plant and equipment and right-of-use assets of approximately HK\$1,295,000 (2021: HK\$11,027,000), HK\$651,000 (2021: HK\$7,480,000) and HK\$1,039,000 (2021:HK\$12,623,000) respectively were included within the beauty and wellness business segment.

3.3 Other segment information are as follows:

	2022	2021
	<i>HK\$'000</i>	<i>HK\$'000</i>
Continuing operations:		
Amounts included in the segment results:		
Depreciation and amortization:		
— Health and medical business	5,215	6,319
— Beauty and wellness business	4,441	9,684
	<u>9,656</u>	<u>16,003</u>
— Unallocated	1,005	787
	<u>10,661</u>	<u>16,790</u>
Addition to non-current assets:		
— Health and medical business	5,417	691
— Beauty and wellness business	83	18,538
	<u>5,500</u>	<u>19,229</u>
— Unallocated	1,184	6
	<u>6,684</u>	<u>19,235</u>

The non-current assets include property, plant and equipment and right-of-use assets.

3.4 Total assets of the Group by operating segments and geographical regions are as follows:

	Health and medical business	Beauty and wellness business	Unallocated corporate assets	Total
	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>
As at 31 December 2022				
Hong Kong	—	—	81,655	81,655
The PRC	57,604	29,378	—	86,982
	<u>57,604</u>	<u>29,378</u>	<u>81,655</u>	<u>168,637</u>
Segment total assets	<u>57,604</u>	<u>29,378</u>	<u>81,655</u>	<u>168,637</u>

	Health and medical business <i>HK\$'000</i>	Beauty and wellness business <i>HK\$'000</i>	Unallocated corporate assets <i>HK\$'000</i>	Total <i>HK\$'000</i>
As at 31 December 2021				
Hong Kong	–	–	109,544	109,544
The PRC	64,261	41,008	–	105,269
Segment total assets	<u>64,261</u>	<u>41,008</u>	<u>109,544</u>	<u>214,813</u>

3.5 Non-current assets of the Group (excluding financial instruments) by operating segments and geographical regions are as follows:

	Health and medical business <i>HK\$'000</i>	Beauty and wellness business <i>HK\$'000</i>	Unallocated corporate assets <i>HK\$'000</i>	Total <i>HK\$'000</i>
As at 31 December 2022				
Hong Kong	–	–	188	188
The PRC	46,149	22,555	–	68,704
Segment total non-current assets	<u>46,149</u>	<u>22,555</u>	<u>188</u>	<u>68,892</u>

	Health and medical business <i>HK\$'000</i>	Beauty and wellness business <i>HK\$'000</i>	Unallocated corporate assets <i>HK\$'000</i>	Total <i>HK\$'000</i>
As at 31 December 2021				
Hong Kong	–	–	9	9
The PRC	45,408	31,505	–	76,913
Segment total non-current assets	<u>45,408</u>	<u>31,505</u>	<u>9</u>	<u>76,922</u>

4. REVENUE

The revenue of the Group is represented by the revenue generated by the health and medical business and beauty and wellness business.

An analysis of revenue by type of service is as follows:

	2022 <i>HK\$'000</i>	2021 <i>HK\$'000</i>
Continuing operations:		
Health and medical business	31,806	39,930
Beauty and wellness business	<u>15,430</u>	<u>29,127</u>
Total revenue recognised at a point in time	<u><u>47,236</u></u>	<u><u>69,057</u></u>

All of the Group's revenue from contracts with customers are generated in the PRC where the goods or services are sold or rendered. All revenue contracts are for the period of one year or less. As permitted by practical expedient under HKFRS 15, the transaction price allocated to these unsatisfied contracts is not disclosed.

5. OTHER INCOMES, GAINS AND LOSSES, NET

	2022 <i>HK\$'000</i>	2021 <i>HK\$'000</i>
Continuing operations:		
Bank interest income	960	155
Government subsidies (<i>Note</i>)	693	682
Sundry income	198	416
Rental concession	947	–
Loss on early release of bonds payable	–	(1,673)
Loss on disposal of property, plant and equipment	<u>(19)</u>	<u>(143)</u>
	<u><u>2,779</u></u>	<u><u>(563)</u></u>

Note: During the year ended 31 December 2022, the Group recognised government grant of approximately HK\$693,000 in respect of COVID-19 related subsidies which is related to Employee Support Scheme provided by Hong Kong Government and government tax policy in PRC. During the year ended 31 December 2021, the Group recognised government grant of approximately HK\$682,000 which was derived from the government tax policy in PRC.

6. FINANCE COSTS

	2022	2021
	<i>HK\$'000</i>	<i>HK\$'000</i>
Continuing operations:		
Interest expenses:		
— Bonds payable	469	1,162
— Other borrowing	316	199
— Lease liabilities	2,545	2,828
	<u>3,330</u>	<u>4,189</u>

7. LOSS BEFORE INCOME TAX

Loss from continuing operations has been arrived at after charging:

	2022	2021
	<i>HK\$'000</i>	<i>HK\$'000</i>
Continuing operations:		
Auditor's remuneration	1,250	1,650
Depreciation of property, plant and equipment	2,514	5,304
Depreciation of right-of-use assets	8,147	11,486
Merchandise purchased and movements in inventories	15,436	20,054
Employee benefit expenses	22,188	29,189
Net allowance of expected credit loss on other receivables	1,176	385

8. INCOME TAX (CREDIT)/EXPENSES

Under the two-tiered profits tax rates regime, the first HK\$2,000,000 of assessable profits of qualifying corporations will be taxed at 8.25%, and assessable profits above HK\$2,000,000 will be taxed at 16.5%. The assessable profits of corporations not qualifying for the two-tiered profits tax rates regime will continue to be taxed at a flat rate of 16.5%.

Under the Law of the PRC on Enterprise Income Tax (the “EIT Law”) and Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiaries is 25% from 1 January 2008 onwards.

The amounts of income tax debited/(credited) to the consolidated statement of profit or loss are as follows:

	2022 <i>HK\$'000</i>	2021 <i>HK\$'000</i>
Continuing operations:		
Current taxation		
PRC enterprise income tax		
— Current year	87	1,445
Deferred taxation	(130)	(1,103)
	<u>(43)</u>	<u>342</u>

No provision for Hong Kong profits tax has been provided as the Group did not generate any assessable profits arising in Hong Kong for the years ended 31 December 2022 and 2021.

9. DISCONTINUED OPERATIONS

- (a) On 9 March 2021 and 19 March 2021, the Group entered into sale and purchase agreements to dispose of two subsidiaries, namely, Celestial Radiant Limited (including its wholly owned subsidiary, Green Securities Limited) and World Path Limited (including its wholly owned subsidiary, Green Asset Management Limited), (collectively, the “**Integrated Finance Business**”) which were principally engaged in securities brokerage, advising on securities and asset management. The disposals were completed on 11 March 2021 and 24 March 2021 respectively, beyond which the Group no longer had control of the Integrated Finance Business and had passed control to the respective acquirers.

The profit for the period from the discontinued operations of the Integrated Finance Business is set out below.

Profit/(loss) for the period from discontinued operations was as follows:

	2021 <i>HK\$'000</i>
Loss for the period of the Integrated Finance Business	(751)
Gain on disposal of the Integrated Finance Business	<u>1,900</u>
Profit from discontinued operations	<u><u>1,149</u></u>

The results of the Integrated Finance Business for the period from 1 January 2021 to the respective disposal dated 11 March 2021 and 24 March 2021, which have been included in the consolidated statement of profit or loss and other comprehensive income/statement of profit or loss of the Group were as follows:

	2021 <i>HK\$'000</i>
Revenue	4
Administrative expenses	<u>(755)</u>
Loss for the period	<u><u>(751)</u></u>

Loss for the year/period from discontinued operations includes the following:

	2021 <i>HK\$'000</i>
Depreciation of property, plant and equipment	5
Depreciation of right-of-use assets	63
Employee benefit expenses	<u>384</u>

Analysis of the cash flow of discontinued operations is as follows:

	2021 <i>HK\$'000</i>
Net cash used in operating activities	(637)
Net cash generated from investing activities	2
Net cash used in financing activities	<u>(64)</u>
Net cash outflow	<u>(699)</u>

- (b) (i) On 9 March 2021, the Group entered into a sale and purchase agreement to dispose of Celestial Radiant Limited (including its wholly owned subsidiary, Green Securities Limited). The disposal was completed on 11 March 2021. Summary of the effects of the disposal is as follows:

Consideration:

	<i>HK\$'000</i>
Consideration received in respect of premium	2,900
Consideration received in respect of reimbursement of net assets value	<u>6,296</u>
Total consideration in cash	<u>9,196</u>

Analysis of assets and liabilities over which control was lost:*HK\$'000***Non-current assets**

Property, plant and equipment	29
Right-of-use assets	<u>285</u>
	<u>314</u>

Current assets

Prepayment, deposits and other receivables	814
Bank balances — trust and segregated accounts	1,651
Bank balances (general accounts) and cash	<u>5,461</u>
	<u>7,926</u>

Current liabilities

Trade payables	1,651
Lease liabilities	292
Other payables	<u>1</u>
	<u>1,944</u>

Net asset disposed	<u>6,296</u>
--------------------	--------------

Gain on disposal of subsidiaries

Consideration received in cash	9,196
Net assets disposed	(6,296)
Transaction costs of disposal	<u>(1,900)</u>

Gain on disposal of subsidiaries	<u><u>1,000</u></u>
----------------------------------	---------------------

Net cash inflow on disposal of subsidiaries

Consideration received in cash	9,196
Less: cash and bank balance disposal of	(5,461)
Less: transaction costs of disposal	<u>(1,900)</u>

Net cash inflow	<u><u>1,835</u></u>
-----------------	---------------------

- (b) (ii) On 19 March 2021, the Group entered into a sale and purchase agreement to dispose of World Path Limited (including its wholly owned subsidiary, Green Asset Management Limited). The disposal was completed on 24 March 2021. Summary of the effects of the disposal is as follows:

Consideration:

	<i>HK\$'000</i>
Consideration received in respect of premium	2,600
Consideration received in respect of reimbursement of net assets value	<u>3,898</u>
Total consideration in cash	<u><u>6,498</u></u>

Analysis of assets and liabilities over which control was lost:

	<i>HK\$'000</i>
Current assets	
Prepayment, deposits and other receivables	4
Bank balances (general accounts) and cash	<u>3,894</u>
Net asset disposed	<u>3,898</u>
Gain on disposal of subsidiaries	
Consideration received in cash	6,498
Net assets disposed of	(3,898)
Transaction costs of disposal	<u>(1,700)</u>
Gain on disposal of subsidiaries	<u><u>900</u></u>
Net cash inflow on disposal of subsidiaries	
Consideration received in cash	6,498
Less: cash and bank balance disposal of	(3,894)
Less: transaction costs of disposal	<u>(1,700)</u>
Net cash inflow	<u><u>904</u></u>

10. LOSS PER SHARE

For continuing operations:

The calculation of the basic and diluted loss per share from continuing operations attributable to owners of the Company is based on the following data:

	2022 <i>HK\$'000</i>	2021 <i>HK\$'000</i>
Loss		
Loss for the purpose of basic and diluted loss per share	<u>(13,229)</u>	<u>(70,329)</u>
	<i>'000</i>	<i>'000</i>
Number of shares		
Weighted average number of ordinary shares in issue	<u>659,895</u>	<u>659,895</u>
Loss per share		
Basic and diluted loss per share (<i>HK cents</i>) (<i>Note</i>)	<u><u>(2.00)</u></u>	<u><u>(10.66)</u></u>

For continuing and discontinued operations:

The calculation of the basic and diluted loss per share from continuing and discontinued operations attributable to owners of the Company is based on the following data:

	2022 <i>HK\$'000</i>	2021 <i>HK\$'000</i>
Loss		
Loss for the purpose of basic and diluted loss per share	<u>(13,229)</u>	<u>(69,180)</u>
	<i>'000</i>	<i>'000</i>
Number of shares		
Weighted average number of ordinary shares in issue	<u>659,895</u>	<u>659,895</u>
Loss per share		
Basic and diluted loss per share (<i>HK cents</i>) (<i>Note</i>)	<u><u>(2.00)</u></u>	<u><u>(10.48)</u></u>

Note:

The basic loss per share is the same as the diluted loss per share as there is no potential ordinary shares in issue in 2022 and 2021.

For discontinued operations:

For the year ended 31 December 2021, basic earnings per share from discontinued operations attributable to owners of the Company based on the profit for the year from discontinued operations of approximately HK\$1,149,000 is 0.18 HK cents.

11. DIVIDENDS

No dividend in respect of the year ended 31 December 2022 (2021: Nil) is to be proposed at the forthcoming annual general meeting.

12. TRADE RECEIVABLES

	2022	2021
	<i>HK\$'000</i>	<i>HK\$'000</i>
Trade receivables	<u>2,855</u>	<u>11,137</u>

The Group's trade receivables generally have a credit period of 90 days. The maximum credit risk exposure at the end of the reporting period is the carrying amount of the trade receivables. The Group does not have any collateral as security. The Group formulates policies and procedures to ensure the sale of products or services to customers with appropriate credit history to minimise the credit risk.

Ageing analysis

The ageing analysis of trade receivables, based on invoice dates, as at 31 December 2022 and 2021 are as follows:

	2022	2021
	<i>HK\$'000</i>	<i>HK\$'000</i>
Within 30 days	2,220	5,156
31–60 days	192	1,080
61–90 days	117	1,202
91–180 days	135	3,496
Over 180 days	<u>191</u>	<u>203</u>
	<u>2,855</u>	<u>11,137</u>

Management assessed the credit quality of the trade receivables in the amount of approximately HK\$2,529,000 (31 December 2021: HK\$7,438,000) that are neither past due nor impaired by reference to the repayment history of those customers.

13. TRADE PAYABLES

	2022 <i>HK\$'000</i>	2021 <i>HK\$'000</i>
Trade payables	<u>4,599</u>	<u>4,255</u>

Ageing analysis

The ageing analysis of trade payables, based on invoice dates, as at 31 December 2022 and 2021 are as follows:

	2022 <i>HK\$'000</i>	2021 <i>HK\$'000</i>
Within 30 days	2,154	1,934
31–60 days	1,435	1,496
61–90 days	782	279
91–180 days	63	439
Over 180 days	<u>165</u>	<u>107</u>
	<u>4,599</u>	<u>4,255</u>

14. ACCRUALS AND OTHER PAYABLES

	2022 <i>HK\$'000</i>	2021 <i>HK\$'000</i>
Bond payable (<i>Note (i)</i>)	–	14,835
Accruals	5,493	7,792
Other borrowings (<i>Note (ii)</i>)	4,816	2,746
Other payables (<i>Note (iii)</i>)	<u>30,280</u>	<u>30,740</u>
	<u>40,589</u>	<u>56,113</u>

Notes:

- (i) On 15 April 2016, the Company issued 8% per annum convertible bonds to Hong Kong Qian Hai Financial Group Limited in an aggregate principal amount of HK\$12,000,000 (the “Qianhai CB”) carrying conversion right to convert into 40,000,000 shares at the conversion price of HK\$0.30 per share (after adjustment) maturing on 15 April 2019. As disclosed in the Company’s announcement dated 20 December 2019, the Company was capable and willing to honour its contractual obligations under the Qianhai CB but due to conflicting instructions given by Zhang Xuejun and Shenzhen Qianhai Shengzun Hualong Holdings Co., Ltd. as to the recipient of cash payment, the redemption process was delayed without any fault on the part of the Company, pending the resolution of litigation and dispute amongst the various parties. After the date of maturity of Qianhai CB on 15 April 2019, the bond was no longer convertible into shares of the Company. Therefore, the Qianhai CB in an aggregate principal amount of HK\$12,000,000 and accrued interest of approximately HK\$2,835,000 was reclassified to accruals and other payables as bond payable in the consolidated statement of financial position as at 31 December 2021. Pursuant to the Court’s order upon the resolution of litigation, the Group fully settled the principal amount and accrued interest of the bond payable in the aggregate amount of approximately HK\$15,000,000 to Shengzun Hualong Holdings Co., Ltd. in the third quarter of 2022.
- (ii) As at 31 December 2022, the other borrowings were unsecured loans from independent third parties, carrying interest rate of 8% (2021: 8%) and repayable on demand.
- (iii) As at 31 December 2022, the payable to the lessor in respect of leased machineries in the amount of approximately HK\$14,923,000 (2021:HK\$13,537,000) was included in the other payables.

15. SHARE CAPITAL

Details of the movements of the share capital for the years ended 31 December 2022 and 2021 are set out as follows:

	Number of shares		Nominal value	
	2022 Number	2021 Number	2022 HK’000	2021 HK’000
Authorised capital:				
As at 1 January	1,000,000,000	5,000,000,000	200,000	200,000
Share consolidation (<i>Note</i>)	–	(4,000,000,000)	–	–
As at 31 December	<u>1,000,000,000</u>	<u>1,000,000,000</u>	<u>200,000</u>	<u>200,000</u>
Issued and fully paid:				
As at 1 January	659,894,693	3,299,473,466	131,979	131,979
Share consolidation (<i>Note</i>)	–	(2,639,578,773)	–	–
As at 31 December	<u>659,894,693</u>	<u>659,894,693</u>	<u>131,979</u>	<u>131,979</u>

Note: The share consolidation became effective on 22 January 2021 on the basis of every five issued and unissued ordinary shares of par value HK\$0.04 each in the share capital of the Company being consolidated into one consolidated share of par value HK\$0.20 each.

MANAGEMENT DISCUSSIONS AND ANALYSIS

BUSINESS REVIEW

Overview

During the year ended 31 December 2022 (the “**Year**”) under review, the Group continued to be principally engaged in provision of (i) health and medical services and (ii) beauty and wellness products and related services.

Health and Medical Business

The health and medical business segment (the “**Health and Medical Business**”) of the Group operates its hospital business in Hunnan Province, China through Li County Phoenix Hospital Company Limited (“**Phoenix Opco**”) and Yiyang Zizhong Kidney Disease Hospital Company Limited (“**Zizhong Opco**”) having the medical organisation operating license granted by the local bureau of the National Health Commission to carry out, amongst other permitted medical treatments, hemodialysis treatment.

Since 2021, China has launched the deepening of reform of medicine and healthcare systems, calling for the need of high-quality services under a sound pricing system to guarantee deserved prices for medical services at local hospitals in China. During the Year, the Group’s Health and Medical Business continued to face challenges from market competitors. Furthermore, operating overheads of the Health and Medical Business have increased due to the implementation of additional hygiene measures and patient handling procedures to alleviate the threat of the epidemic.

In the third quarter of 2022, the Group resolved to relocate one of its hospitals to another newly-leased premises with bigger area. Through the relocation to bigger premises, the management is hopeful that the Group will be in a better market position to grasp the market share and enhance its operational capacity. The relocation is scheduled to be completed during the second half of 2023.

Beauty and Wellness Business

The beauty and wellness business (the “**Beauty and Wellness Business**”) of the Group operates its beauty parlors under the brand name of 瑪莎 (Marsa) in Shenzhen, China through selling of beauty and wellness products and related services to local customers.

The performance of the Beauty and Wellness Business continued to be sluggish during the Year due to the abrupt downturn of the service industry and weakened consumer market as a result of the change in consumption pattern during the epidemic. In addition, during the Year, certain beauty parlors of the Group in Shenzhen were temporarily suspended for business to comply with hygiene control measures under the guidance of local governmental authorities.

Prospect

The prolonged effect of COVID-19 has caused uncertainties of economy and business environment during the past few years. With the gradual lifting the epidemic related measures in China in December 2022, the Group will closely review the latest business and market development and evaluate potential business expansion opportunities as and when they arise. Save as the aforementioned hospital relocation, the acquisition and expansion plans of the Group's hospital business have slowed down due to the deepening of reform of medicine and healthcare systems in 2021. Pending the clarification of market reactions under the reform, the Group does not intend to commit to any substantial acquisition or expansion plans under any specified timeline prematurely..

Events with Impact on the Financial Position and the Business Operations

- (i) During the Year, certain beauty parlors of the Group in Shenzhen were temporarily suspended for business to comply with certain hygiene control measures under the guidance of local governmental authorities, having impact on the financial position or the business operations of the Group.
- (ii) In the third quarter of 2022, the Group fully settled an outstanding bond payable with accrued interest in the amount of approximately HK\$15,000,000.
- (iii) In the third quarter of 2022, the Group resolved to relocate one of its hospitals to another newly-leased premises with bigger area to put itself in a better market position to grasp the market share and enhance its operational capacity.

FINANCIAL REVIEW

Revenue

The Group's revenue for the Year was approximately HK\$47,236,000 (2021: HK\$69,057,000), representing a decrease of approximately 31.60% as compared to last year. The decrease in the revenue was mainly due to uncertainties in the economic and business environment and weakened consumer market in China.

Direct Costs and Operating Expenses

The Group's direct costs and operating expenses for the Year was approximately HK\$21,089,000 (2021: HK\$31,451,000), representing a decrease of approximately 32.95% as compared to last year. The decrease in the direct costs and operating expenses was generally in line with the decrease in revenue.

Gross Profit and Gross Profit Margin

The Group's gross profit for the Year was approximately HK\$26,147,000 (2021: HK\$37,606,000), representing a decrease of approximately 30.47% as compared to last year. The Group's gross profit margin for the Year was 55.35% (2021: 54.45%).

Selling Expenses

The Group's selling expenses for the Year amounted to approximately HK\$12,647,000 (2021: HK\$21,347,000), representing a decrease of approximately 40.76% as compared to last year. The decrease in the selling expenses was generally in line with the decrease in revenue.

Administrative Expenses

The Group's administrative expenses for the Year amounted to approximately HK\$23,821,000 (2021: HK\$37,441,000), representing a decrease of approximately 36.38% as compared to last year. The decrease in the administrative expenses was mainly attributable to implementation of cost control measures.

Impairment Testing on Cash-Generating Unit of the Health and Medical Business Business

The management regards the Health and Medical Business as a separately identifiable cash-generating unit. Management carried out an impairment assessment for the Health and Medical Business, including property, plant and equipment and right-of-use assets, which have an impairment indicator.

The management performed an impairment assessment on the cash-generating unit in respect of the Health and Medical Business at the end of the reporting period by reference to the valuation prepared by an independent valuer. The valuation was based on (a) the five years cash flow projections which are discounted using the discount rate of 10.04%; (b) a terminal value calculated using a discount rate of 3%; and (c) the latest financial forecast figures provided by the management of Phoenix Opco and Zizhong Opco taking into account the potential adverse impact on the performance of the Health and Medical Business as a result of prolonged effect of the COVID-19 and the latest market development. The impairment losses

of goodwill, property, plant and equipment and right-of-use assets were approximately HK\$Nil (2021: HK\$8,566,000), HK\$Nil (2021: HK\$1,089,000) and HK\$Nil (2021: HK\$6,348,000) respectively being recognised in the consolidated statement of profit or loss for the Year.

Impairment Testing on Cash-Generating Unit of Beauty and Wellness Business

The management regards the Beauty and Wellness Business as a separately identifiable cash-generating unit. Management carried out an impairment assessment for the Beauty and Wellness Business, including property, plant and equipment and right-of-use assets, which have an impairment indicator.

The management performed an impairment assessment on the cash-generating unit in respect of Beauty and Wellness Business at the end of the reporting period by reference to the valuation prepared by an independent valuer. The valuation was based on (a) the five years cash flow projections which are discounted using the discount rate of 13.2%; (b) a terminal value calculated using a discount rate of 3% and (c) the updated financial forecast figures provided by the management of Beauty and Wellness Business taking into account the potential adverse impact on the performance of the Beauty and Wellness Business as a result of prolonged effect of the COVID-19 and the latest market trend and environment. The impairment losses of the trademark user right and technical know-how, property, plant and equipment and right-of-use assets were approximately HK\$1,295,000 (2021: HK\$11,027,000), HK\$651,000 (2021: HK\$7,480,000) and HK\$1,039,000 (2021: HK\$12,623,000) respectively being recognised in the consolidated statement of profit or loss for the Year.

Finance Costs

The Group's finance costs for the Year amounted to approximately HK\$3,330,000 (2021: HK\$4,189,000). Details of the finance costs are set out in Note (6) to the consolidated financial statements.

Loss for the Year from Continuing Operations

The Group's net loss for the Year from continuing operations was approximately HK\$13,814,000 (2021: HK\$73,409,000).

Profit for the Year from Discontinued Operations

The Group's net profit for the Year from discontinued operations was HK\$Nil (2021:HK\$1,149,000).

USE OF PROCEEDS OF EQUITY FUND RAISING ACTIVITIES

The Company had not conducted any equity fund raising activities during the Year.

The amount of proceeds brought forward from issue of equity securities (including securities convertible into equity securities) made in previous financial year(s) and details of the use of such proceeds are set out as below:

Date of announcement	Fund raising activity	Net proceeds raised	Unutilized equity fund raising proceeds brought forward from previous years and the intended use of proceeds	Actual use of proceeds
3 April 2019	The Company issued 754,716,981 ordinary shares to Jumbo Faith at the subscription price of HK\$0.212 per under specific mandate, which was completed on 3 April 2019.	Approximately HK\$156 million	As to the remaining net proceeds of approximately HK\$15 million being set aside for the cash redemption of the Qianhai 2016 CB maturing in April 2019.	Fully utilized as intended during the Year. Further details are disclosed in Note (14) to the consolidated financial statements.

Date of announcement	Fund raising activity	Net proceeds raised	Unutilized equity fund raising proceeds brought forward from previous years and the intended use of proceeds	Actual use of proceeds
15 December 2020	The Company issued and allotted 1,649,736,733 ordinary shares under the rights issue on the basis of one rights share for every one existing share held on the record date at the subscription price of HK\$0.06 per rights share. The rights issue became unconditional on 9 December 2020.	Approximately HK\$95.9 million	<p>As to the remaining net proceeds of HK\$80.9 million for the potential acquisitions, expansion and equipment purchase of the Group's hospital business.</p> <p>Subsequent to the period end, the Board resolved to change the use of proceeds of HK\$19 million out of the remaining net proceeds for the Group's general working capital and meeting the Group's liabilities and expenses (such as overheads and rental payments, staff costs, professional fees) as they fall due. The Board is of the view that such change is in the best interests of the Company and its shareholders as a whole, as it is vital to have sufficient working capital to maintain the Group's businesses as a going concern,.</p>	<p>By the end of 31 December 2022, approximately HK\$3,474,000 (equivalent to RMB3,068,000) was used for relocation of a hospital of the Health and Medical Business of the Group in China.</p> <p>Save as the aforementioned hospital relocation, the acquisition and expansion plans of the Group's hospital business have slowed down due to the deepening of reform of medicine and healthcare systems in 2021. Pending the clarification of market reactions under the reform of medicine and health care systems, the Group does not intend to commit to any substantial acquisition or expansion plans under any specified timeline prematurely.</p>

LIQUIDITY AND FINANCIAL RESOURCES

As at 31 December 2022, the Group had total assets of approximately HK\$168,637,000 (31 December 2021: HK\$214,813,000) and debts of approximately HK\$72,517,000 (31 December 2021: HK\$83,107,000), giving rise to a leverage ratio (defined as debt to total assets) of approximately 43.00% (31 December 2021: 38.69%).

As at 31 December 2022, the Group had net current assets of approximately HK\$41,784,000 (31 December 2021: HK\$61,353,000), being the surplus of current assets of approximately HK\$99,745,000 (31 December 2021: HK\$137,891,000) over the current liabilities of approximately HK\$57,961,000 (31 December 2021: HK\$76,538,000), giving rise to a current ratio of approximately 1.72 (31 December 2021: 1.80).

As at 31 December 2022, the Group had cash and bank balances of approximately HK\$81,742,000 (31 December 2021: HK\$110,743,000).

GEARING RATIO

As at 31 December 2022, the gearing ratio of the Group (defined as debt to equity) was approximately 139% (31 December 2021: 125%). For this purpose, debt includes bonds payable, other borrowings and lease liabilities, if applicable.

SIGNIFICANT INVESTMENT HELD

The Group had no significant investment held as at 31 December 2022.

ACQUISITION AND DISPOSAL OF SUBSIDIARIES

The Group had no material acquisition or disposal of subsidiaries during the Year.

The Group disposed of the Integrated Financial Business in March 2021 for an aggregate cash consideration of HK\$5,500,000 and recorded a gain on disposal in the amount of approximately HK\$1,900,000.

CHARGES ON ASSETS

None of the Group's assets was pledged to secure any facilities and borrowings granted to the Group as at 31 December 2022.

CONTINGENT LIABILITIES

The Group had no material contingent liabilities as at 31 December 2022.

FOREIGN EXCHANGE EXPOSURE

The Group's business transactions were mainly carried out in Hong Kong dollars and Renminbi. The Group was not engaged in any hedging measures during the Year. The Group will regularly review its position and may use financial measures to hedge its foreign currency exposure if it considers the risk to be significant.

CAPITAL STRUCTURE

Save as disclosed herein, there were no changes in the capital structure of the Company for the year ended 31 December 2021, the year ended 31 December 2022 and up to the date of this announcement.

(A) Share Capital

Details of the movements of the share capital for the Year and the year ended 31 December 2021 are set out in Note (15) to the consolidated financial statements.

(B) Share Options

Old Share Option Scheme

The old share option scheme (the “**Old Share Option Scheme**”) adopted by the Company on 2 September 2006 lapsed on 2 September 2016 pursuant to the terms of the Old Share Option Scheme.

New Share Option Scheme

At the annual general meeting of the Company held on 26 June 2019, a new share option scheme (the “**New Share Option Scheme**”) was approved by the shareholders of the Company. The New Share Option Scheme has a lifespan of 10 years. At the annual general meeting of the Company held on 26 June 2019, the Scheme Mandate Limit was approved to allow the Company to grant options for the holders thereof to subscribe up to 147,326,614 shares (before adjustments upon the share consolidation), representing 10% of the shares in issue as the date of approval of the scheme. Details of the New Share Option Scheme are set out in the circular of the Company dated 24 May 2019.

No share options were granted under the New Share Option Scheme for the Year and the year ended 31 December 2021 and there were no outstanding share options as at 31 December 2022 and 2021. As at the date of this announcement, the maximum number of options which can be granted under the New Share Option Scheme was 29,465,322 consolidated shares (equivalent to 147,326,614 options before the five-to-one share consolidation took effect on 22 January 2021), representing 4.47% of the existing issued share capital of the Company. The remaining lifespan of the New Share Option Scheme is 6 years and 3 months.

(C) Convertible Bonds

There were no outstanding convertible bonds as at 31 December 2022 and 2021.

DIVIDEND

The Directors do not recommend the payment of any dividend for the Year (2021: Nil).

HUMAN RESOURCES

As at 31 December 2022, the Group has 180 employees in Hong Kong and China. Employees' remuneration, promotion and salary increments are assessed based on both individuals' and the Group's performance, professional and working experiences and by reference to prevailing market practices and standards.

LITIGATION

Save as disclosed below, neither the Company nor any other member of the Group was engaged in any litigation or claim of material importance known to the Directors to be pending or threatened against any member of the Group during the Year and up to the date of this announcement:

The Company issued 8% per annum convertible bonds to Hong Kong Qian Hai Financial Group Limited ("**HK Qianhai Financial**") in an aggregate principal amount of HK\$12,000,000 (the "**2016 CB**") carrying conversion right to convert into the shares of the Company. The 2016 CB matured on 15 April 2019 without conversion. At or around the maturity date of the 2016 CB, the Company received conflicting instructions from Mr. Zhang Xuejun (張學軍) ("**Mr. Zhang**") and another entity named 深圳市前海盛尊華龍控股有限公司 (Shenzhen Qianhai Shengzun Hualong Holdings Co., Ltd.) ("**Shengzun Hualong**"), both purporting to have the authority from the holder of the 2016 CB and each purporting to give different payment instructions to the Company regarding the recipient of the cash redemption amount. Shengzun Hualong commenced legal action against Mr. Zhang, HK Qianhai Financial

and the Company (the “**Litigation**”) seeking to recover the cash redemption amount of the 2016 CB. The Company has now received the second instance judgment handed down by Guangdong Shenzhen Intermediate People’s Court (the “**Court**”), confirming the first instance judgment, under which the Court ruled that the subscription agreement in respect of the 2016 CB were entered into with the Company by Mr. Zhang, under the entrustment of Shengzun Hualong and sub-delegating to be entered in the name of HK Qianhai Financial, and ordering the Company to pay the principal and interest in the aggregate amount of RMB12.88 million directly to Shengzun Hualong. The Court also supported the Company’s case that the delay in repayment was due to no fault on the part of the Company, such that the Company shall not be responsible for any late penalty. The Court ordered that the late penalty payable to Shengzun Hualong shall be borne by Mr. Zhang. After receiving the above judgement, the Group fully settled the principal amount and accrued interest in the aggregate amount of approximately HK\$15,000,000 to Shengzun Hualong in the third quarter of 2022.

OTHER INFORMATION

PURCHASE, SALE OR REDEMPTION OF SHARES

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company’s securities listed on the Stock Exchange during the Year.

CORPORATE GOVERNANCE

The Company and the Directors confirm, to the best of their knowledge, that the Company complied with the code provisions set out in the Corporate Governance Code (the “**CG Code**”) as set out in Appendix 14 to the Listing Rules throughout the Year, except the deviation disclosed in the following paragraph:

With respect to Code Provision D.2.5, an issuer should have an internal audit function and issuers without an internal audit function should review the need for one on an annual basis and should disclose the reasons for the absence of such a function in the Corporate Governance Report. Due to the size and scale of operations, the Group did not have internal audit function during the Year.

The Company has engaged Crowe (HK) Risk Advisory Limited as an external consultant to establish an internal audit function for the Year. The external consultant has assisted the audit committee in carrying out an independent review on the adequacy and effectiveness of the risk management and internal control systems of the Group, and has reported the status of its review to the audit committee on a regular basis. The Group has formulated an internal audit charter to define the scope and duties and responsibilities of the internal audit function and its reporting protocol.

MODEL CODE ON SECURITIES TRANSACTION BY DIRECTORS OF LISTED ISSUERS

The Company follows the Model Code for Securities Transactions by Directors of Listed Issuers in Appendix 10 to the Listing Rules (the “**Model Code**”) as the code of conduct for Directors in their dealings in the Company’s securities. Upon specific enquiry by the Company, all Directors confirmed that they have complied with the required standard set out in the Model Code throughout the Year.

AUDIT COMMITTEE

The audit committee was established by the Company with written terms of reference in compliance with the requirements set out in Appendix 14 to the Listing Rules.

Currently, the audit committee consists of three independent non-executive Directors, namely Mr. David Tsoi (Chairman), Mr. Wu Hong and Mr. Wang Chunlin. One out of three audit committee members, Mr. David Tsoi, possesses recognised professional qualifications in accounting and has wide experience in audit and accounting.

The audited consolidated financial statements of the Group for the Year have been reviewed by the audit committee of the Company, which is of the opinion that such statements complied with applicable accounting standards and the Listing Rules, and that adequate disclosures have been made.

SCOPE OF WORK OF AUDITOR

The figures in respect of the Group’s consolidated statement of financial position, consolidated statement of profit or loss, consolidated statement of profit or loss and other comprehensive income and the related notes thereto for the Year as set out in this preliminary announcement of the Group’s result have been agreed by the Group’s auditor, HLB Hodgson Impey Cheng Limited (“**HLB**”), to the amounts set out in the Group’s audited consolidated financial statements for the Year. The work performed by HLB in this respect did not constitute an assurance engagement and consequently no opinion or assurance conclusion has been expressed by HLB on the preliminary results announcement.

PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT AND ANNUAL REPORT

This annual results announcement has been published on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (<http://www.iraia.com/listco/hk/greeninternational/>) (collectively referred to as the “Websites”). The 2022 annual report of the Company containing all the information required by the Listing Rules will be dispatched to the shareholders of the Company and published on the Websites on or before 30 April 2023. The Company will give further notice on the proposed date of the forthcoming annual general meeting of the Company (the “AGM”) and the book closure period for the purpose of ascertaining shareholders’ eligibility to attend and vote at the AGM.

APPRECIATION

I would like to express my gratitude to our fellow directors and all employees for their valuable contribution. On behalf of the Board, I would also like to extend my sincere thanks to our shareholders, customers, suppliers, bankers and business associates for their continued support.

By Order of the Board
Green International Holdings Limited
Yu Zhoujie
Chairman

Hong Kong, 30 March 2023

As at the date of this announcement, the executive Directors are Mr. Liu Dong and Mr. Yu Xiangjin; the non-executive Directors are Mr. Chen Hanhong and Mr. Yu Zhoujie (Chairman); and the independent non-executive Directors are Mr. Wu Hong, Mr. David Tsoi and Mr. Wang Chunlin.